NUFORMIX PLC

Share Issue/Capital Change • Mar 28, 2022

National Storage Mechanism | Additional information

RNS Number : 1492G

Nuformix PLC

28 March 2022

28 March 2022

Nuformix plc

("Nuformix" or the "Company")

NXP004 Patent

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the publication of an international patent in relation to the Company's NXP004 asset, which comprises novel forms of olaparib (the "Patent").  Olaparib is currently marketed by AstraZeneca, under the Lynparza® brand name for the treatment of adults with suspected deleterious germline or somatic BRCA gene mutated ovarian, breast, or pancreatic cancer, or for suspected deleterious germline or somatic HRR gene mutated prostate cancer.

The application for the Patent, relating to new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them, was made by the Company's wholly owned subsidiary Nuformix Technologies Limited and was filed in September 2020.  The Company filed a second patent application, complementing the Patent, in November 2021 and this remains pending.

The olaparib oxalic acid cocrystals covered by the Patent may be used in the same way as olaparib. Olaparib is useful in treating diseases that benefit from PARP (Poly ADP Ribose Polymerase) inhibition. These include cancer, fibrosis, inflammatory conditions (e.g. asthma, colitis, arthritis), neurological diseases (e.g. neurodegeneration, neurotrauma, stroke), cardiovascular conditions, ophthalmic degenerative diseases, vascular diseases (e.g. diabetic complications, atherosclerosis), and various forms of critical illness (e.g. septic shock, ALI, acute liver failure). The olaparib oxalic acid cocrystals covered by the Patent may, therefore, ultimately be useful for the treatment of such diseases, disorders, and conditions.

The Company looks forward to providing further updates on progress with NXP004 and the Company's other assets in due course.

Commenting, Alastair Riddell, Executive Chairman of Nuformix, said: "We are pleased to see the progression of the application for the Company's first patent in relation to NXP004 to the publication stage.  We believe NXP004 has significant potential and look forward to the granting of the Patent in due course.  We are continuing to conduct further research and development activities on NXP004, as well as investigating future commercial opportunities.  Whilst there remains much to be done, I look forward to making further announcements on our progress in the future."

Enquiries:

Nuformix plc
Dr Alastair Riddell, Executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
John Howes (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCLDLFLLXLLBBK